Back to Search
SHANNON TOMLINSON, M.D.
M.D.
Radiation Oncology Physician
NPI: 1679621395IndividualAccepts Medicare
Specialties, Licenses & Credentials
Radiation Oncology PhysicianPrimary
Radiology — Radiation Oncology
Code: 2085R0001X
9901626(NC)
CMS Specialties
PrimaryRADIATION ONCOLOGY
Education
UNIVERSITY OF TOLEDO COLLEGE OF MEDICINE
Class of 1998
Research & Publications (20)
New approaches to structure-based discovery of dengue protease inhibitors.
PMID 19519486·Infect Disord Drug Targets·2009
6-review
Structure-based discovery of dengue virus protease inhibitors.
PMID 19428601·Antiviral Res·2009
6-review
Substrate inhibition kinetic model for West Nile virus NS2B-NS3 protease.
PMID 18855422·Biochemistry·2008
8-other
Monomer conversion and hardness of novel dental cements based on ethyl cyanoacrylate.
PMID 16949146·Dent Mater·2007
4-observational
Characterisation of antibacterial Australian medicinal plant extracts by investigation of the mechanism of action and the effect of interfering substances.
PMID 16187270·J Basic Microbiol·2005
7-preclinical
Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer--a phase II study.
PMID 11988109·BMC Cancer·2002
3-trial
A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration.
PMID 19264882·Invest Ophthalmol Vis Sci·2009
7-preclinical
App1: an antiphagocytic protein that binds to complement receptors 3 and 2.
PMID 19109138·J Immunol·2009
7-preclinical
Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury.
PMID 19386604·J Biol Chem·2009
8-other
A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice.
PMID 19620784·J Clin Invest·2009
7-preclinical
A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury.
PMID 19017999·J Immunol·2008
7-preclinical
Modulation of protective T cell immunity by complement inhibitor expression on tumor cells.
PMID 18701498·Cancer Res·2008
7-preclinical
Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
PMID 18680277·J Med Chem·2008
7-preclinical
Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2.
PMID 18640038·Bioorg Med Chem Lett·2008
7-preclinical
Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection.
PMID 18561323·Int J Cancer·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 810 FAIRGROVE CHURCH RD
HICKORY, NC 28602 - Phone
- (828) 326-3856
Quick Facts
- NPI
- 1679621395
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 28
- Publications
- 20
Are you this provider?
Claim Your Profile